Drug details

Byooviz (ranibizumab-nuna injection, for intravitreal use)

type of Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors

Byooviz (ranibizumab-nuna) is vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). 

This drug may have the following side effects:

• eye irritation,
• eye itching
• vision problems, and
• eye “floaters,”
• cataracts,
• eye pain, 
• dry eye,
• blood spots in the whites of the eyes (conjunctival hemorrhage), 
• increased intra-ocular pressure, 
• eye inflammation, 
• foreign body sensation in eyes,
• increased tearing, 
• swelling of eyelids, 

The following drugs are related to Byooviz, either as a replacement or used together:

• Eylea (aflibercept)
• Beovu (brolucizumab-dbll for intravitreal injection)
• Lucentis (ranibizumab injection)
• Macugen (pegaptanib sodium)
• Syfovre (pegcetacoplan injection, for intravitreal use)
• Visudyne (verteporfin injection)